Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Goldman Takes Baxter off 'Recommended List'


Goldman Sachs removed Baxter International (BAX) from its recommended list, and now rates it as market outperform.

Analyst Lawrence Keusch says second quarter earnings per share excluding charges were in line with estimates, but he says the $2.02 billion sales figure was $70 million below his estimate, primarily due to weaker than expected results in its BioSciences (plasma; 37% of revenues) and Renal (dialysis equipment; 25% of revenues) divisions.

Keusch thinks 2002 guidance will be back-end loaded; Renal sales are likely to be flat for the year. He thinks Baxter will need to use gains from a currency translation to meet its low-teens sales growth target for the year. Keusch also thinks a lack of near-term catalysts is likely to plague the stock.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus